Merck says COVID pill 'active' against Omicron

The Nation's Leading Newspaper

1/29/2022 8:15:00 AM

Merck’s anti-Covid pill remains “active” against the Omicron variant, the US drugmaker said Friday, citing results from six laboratory studies.

The Nation's Leading Newspaper

WASHINGTON, United States — Merck’s anti-Covid pill remains “active” against the Omicron variant, the US drugmaker said Friday, citing results from six laboratory studies.The oral treatment, called molnupiravir, is taken within five days of symptom onset and was shown in a pre-Omicron trial of 1,400 participants to reduce Covid hospitalizations and deaths by 30 percent among at-risk people.

The latest in vitro studies, based on cell-based assays, were conducted independently by researchers in six countries: Belgium, Germany, the Czech Republic, Poland, the Netherlands and the United States.The results show “that molnupiravir has consistent antiviral activity against Omicron, the primary variant circulating globally,” said Dr. Dean Y Li, the president of Merck Research Laboratories, in a statement.

Read more: Manila Bulletin News »

Pateros’ active COVID-19 cases dropThe number of active COVID-19 cases in Pateros has decreased as the DOH noted that the cases in the NCR continue to drop amid the spread of the Omicron variant.

Eastern Visayas has 28 confirmed COVID-19 Omicron casesRegion 8 has a total of 220 cases of variants of concern during the two-year pandemic, with 55% of the cases being Delta and 13% Omicron.

As Omicron ebbs, England revives Plan A: living with COVID - BusinessWorld OnlineLONDON — After an uncomfortable but relatively brief return to coronavirus restrictions triggered by the Omicron variant, England is going back to “Plan A” — learning to live with a disease that is probably here to stay. The bet is that booster jabs, antiviral pills, and Omicron’s lower severity will enable the government to manage […]

PH COVID-19 cases approach 3.5 million with 18,191 infections — DOHThe Philippines on Thursday is nearing the 3.5 million mark of COVID-19 infections in the country, with the addition of 18,191 new COVID-19 cases. | JEMendozaINQ

EU watchdog approves Pfizer COVID-19 pill PaxlovidThe EU&39;s drug watchdog approved Pfizer&39;s coronavirus pill on Thursday, making it the first oral antiviral treatment for the disease to be authorized in Europe.

80% of of vaccinated adult Filipinos willing to get COVID booster shot, survey showsEighty percent or four out of five vaccinated adult Filipinos are willing to get a booster dose against COVID-19, the latest SWS survey released Thursday night showed. | NAMercadoINQ NAMercadoINQ Of course, because most Filipinos do whatever they are told to do. Sad, because they are some of the kindest people in the world.

Agence-France-Presse WASHINGTON, United States — Merck’s anti-Covid pill remains “active” against the Omicron variant, the US drugmaker said Friday, citing results from six laboratory studies. The oral treatment, called molnupiravir, is taken within five days of symptom onset and was shown in a pre-Omicron trial of 1,400 participants to reduce Covid hospitalizations and deaths by 30 percent among at-risk people. The latest in vitro studies, based on cell-based assays, were conducted independently by researchers in six countries: Belgium, Germany, the Czech Republic, Poland, the Netherlands and the United States. The results show “that molnupiravir has consistent antiviral activity against Omicron, the primary variant circulating globally,” said Dr. Dean Y Li, the president of Merck Research Laboratories, in a statement. These findings “provide additional confidence in the potential of molnupiravir as an important treatment option for certain adults with mild to moderate Covid-19 who are at high risk for progressing to severe disease,” he said. The effectiveness of molnupiravir against Omicron has yet to be evaluated in clinical trials, said Merck, known as MSD outside the United States and Canada. The treatment, sometimes marketed under the name Lagevrio, has been approved in more than 10 countries, including the United States, the United Kingdom and Japan. Washington has paid $2.2 billion for 3.1 million courses of Merck’s treatment, of which two million have already been delivered, according to the company. A total of 10 million courses were produced in 2021, and Merck plans to produce an additional 20 million this year. Eight capsules of molnupiravir are taken orally for five days, for a total of 40 capsules. Pfizer has also developed an anti-Covid pill, marketed as Paxlovid. Pfizer’s pill reduced the same outcomes as Merck’s by almost 90 percent, is authorized for people aged 12 and up, and has fewer overall safety concerns. The US pharmaceutical company said in mid-January that in vitro studies suggest Paxlovid should remain effective against Omicron. Other treatments for Covid-19, such as monoclonal antibodies from Regeneron and Eli Lilly, have been shown to be ineffective against Omicron. The US Food and Drug Administration restricted their use earlier this week. The Omicron strain has numerous mutations, particularly in the spike protein that dots the virus’s surface and is key to entering human cells. As a result, some treatments are no longer effective against the variant. But antiviral pills do not target the protein, meaning they should be variant proof and encouraging confidence in the drugs’ lasting effectiveness, including against future variants.